Jun 18, 2020
Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 31, 2020
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
May 13, 2020
Kanazawa University Research: Notorious Cancer Protein Mutations Cooperate to Proliferate Disease
Nov 13, 2019
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
Aug 05, 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Jun 13, 2019
PMV Pharma Appoints Deepika Jalota, Pharm.D. as Senior Vice President and Head of Regulatory Affairs
Jun 03, 2019
Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO
May 22, 2019
Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers
Apr 16, 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Apr 03, 2019
Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
Mar 25, 2019
Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting
Mar 25, 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Feb 27, 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Dec 19, 2018
Ascentage Pharma Announces Strategic Collaboration with Genor Biopharma
Dec 02, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego
Nov 30, 2018
Aprea Therapeutics Closes EUR 50 Million Financing
Nov 29, 2018
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Aug 14, 2018
Actavalon Announces Appointments of Dr. John Hood to Its Board of Directors
Jun 17, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
Apr 16, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago